ECSP109983A - Formulaciones de liposomas de compuestos de acido boronico - Google Patents

Formulaciones de liposomas de compuestos de acido boronico

Info

Publication number
ECSP109983A
ECSP109983A EC2010009983A ECSP109983A ECSP109983A EC SP109983 A ECSP109983 A EC SP109983A EC 2010009983 A EC2010009983 A EC 2010009983A EC SP109983 A ECSP109983 A EC SP109983A EC SP109983 A ECSP109983 A EC SP109983A
Authority
EC
Ecuador
Prior art keywords
liposomes
boronic acid
compound
formulations
acid compound
Prior art date
Application number
EC2010009983A
Other languages
English (en)
Inventor
Anthony Huang
Bing Luo
Jinkang Wang
Yuanpeng Zhang
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ECSP109983A publication Critical patent/ECSP109983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición de liposoma que comprende liposomas con un compuesto inhibidor de la proteasoma con péptido de ácido borónico atrapado en los liposomas. Más específicamente, los liposomas que tienen un compuesto de la Fórmula I ó II atrapados en el compartimento acuoso interior se cargan con un compuesto peptídico de ácido borónico, para formar un compuesto de éster boronato dentro del compartimento acuoso liposomal. En una modalidad, los liposomas tienen un recubrimiento externo de cadenas poliméricas hidrófilas y se utilizan para tratar un tumor sólido en un sujeto.
EC2010009983A 2007-08-21 2010-02-22 Formulaciones de liposomas de compuestos de acido boronico ECSP109983A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95704907P 2007-08-21 2007-08-21

Publications (1)

Publication Number Publication Date
ECSP109983A true ECSP109983A (es) 2010-04-30

Family

ID=39772869

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009983A ECSP109983A (es) 2007-08-21 2010-02-22 Formulaciones de liposomas de compuestos de acido boronico

Country Status (16)

Country Link
US (1) US20090092662A1 (es)
EP (1) EP2190412A2 (es)
JP (1) JP2010536875A (es)
KR (1) KR20100066515A (es)
CN (1) CN101795672A (es)
AU (1) AU2008288920A1 (es)
BR (1) BRPI0815713A2 (es)
CA (1) CA2697044A1 (es)
CO (1) CO6260057A2 (es)
EA (1) EA201070297A1 (es)
EC (1) ECSP109983A (es)
MX (1) MX2010002101A (es)
NI (1) NI201000030A (es)
SV (1) SV2010003487A (es)
WO (1) WO2009026430A2 (es)
ZA (1) ZA201002011B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125388B2 (en) * 2007-10-31 2018-11-13 Akonni Biosystems, Inc. Integrated sample processing system
WO2009155135A1 (en) * 2008-06-18 2009-12-23 Alza Corporation Composition comprising liposome-entrapped doxorubicin and methods of admnistration for treatment of multiple myeloma
US9034829B1 (en) * 2011-10-27 2015-05-19 Northwestern University pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
CN111116622A (zh) 2014-02-03 2020-05-08 俄亥俄州创新基金会 硼酸酯和其药物制剂
JP6715265B2 (ja) * 2015-05-04 2020-07-01 フェルザンティス アーゲーＶｅｒｓａｎｔｉｓ Ａｇ 膜内外ｐＨ勾配ベシクルを調製する方法
CN109045272A (zh) * 2018-08-01 2018-12-21 厦门市壳聚糖生物科技有限公司 一种硼替佐米磷脂复合物及其制备方法与应用
WO2021096951A1 (en) * 2019-11-11 2021-05-20 Washington University Liposome compositions and methods of treatment targeted to tumor endothelium
WO2024035871A1 (en) * 2022-08-12 2024-02-15 Aviko Radiopharmaceuticals, Llc Small molecules for boron neutron capture therapy
US20240132524A1 (en) * 2022-09-21 2024-04-25 Aviko Radiopharmaceuticals, Llc Small molecules for boron neutron capture therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1396270E (pt) * 2002-09-09 2006-08-31 Trigen Ltd Processo para a preparacao de compostos uteisncomo intermidiarios.
WO2006047409A2 (en) * 2004-10-22 2006-05-04 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds

Also Published As

Publication number Publication date
WO2009026430A3 (en) 2009-11-26
SV2010003487A (es) 2010-08-10
AU2008288920A1 (en) 2009-02-26
EP2190412A2 (en) 2010-06-02
CA2697044A1 (en) 2009-02-26
KR20100066515A (ko) 2010-06-17
CN101795672A (zh) 2010-08-04
JP2010536875A (ja) 2010-12-02
EA201070297A1 (ru) 2010-08-30
ZA201002011B (en) 2011-05-25
NI201000030A (es) 2010-07-29
US20090092662A1 (en) 2009-04-09
WO2009026430A2 (en) 2009-02-26
BRPI0815713A2 (pt) 2015-02-10
MX2010002101A (es) 2010-03-26
CO6260057A2 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
ECSP109983A (es) Formulaciones de liposomas de compuestos de acido boronico
UY29191A1 (es) Formulaciones liposómicas de compuestos de ácido borónico
ECSP14010763A (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos
CL2016001553A1 (es) Medios para cultivo celular
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
UY31765A (es) Dihidropirazolonas sustituidas y su uso
ECSP13012692A (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
WO2011140353A3 (en) Remote phosphor tape for lighting units
ECSP13012844A (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
EA201070296A1 (ru) Липосомные композиции для введения in vivo соединений бороновой кислоты
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CR20130684A (es) Composición limpiadora que comprende un agente gelificante y un tensioactivo empumante
CL2012002173A1 (es) Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
AR086557A1 (es) Soporte de colageno enrollado
AR063894A1 (es) Uso de un acido indazolmetoxialcanoico para preparar una composicion farmaceutica
AU319472S (en) Shoe box
AR107492A1 (es) Composición de desbridamiento para el tratamiento de heridas
PA8845501A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes de curación de heridas
AU332309S (en) Portable accommodation and/or office unit
AU320019S (en) Tampon case
AU320020S (en) Tampon case